A04AA02 - Granisetron |
Probably not porphyrinogenic |
PNP |
Rationale
Substrate for CYPs 3A4 and 3A5. No data pointing to clinical CYP-induction.
Chemical description
Selective 5-HT-antagonist used as prophylaxis or treatment of postoperative nausea and nausea under chemotherapy, 2-9 mg/d perorally or parenterally. Metabolized mainly by CYP3A4. No instances of CYP-induction observed clinically.
IPNet drug reports
Uneventful use reported in 2 patients with acute porphyria.
Similar drugs
References
| # | Citation details | PubMed ID |
|---|---|---|
| Porphyria Drug Lists | ||
| 1. | French List
Centre Français des Porphyries
|
|
Tradenames